<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11742482</article-id><article-id pub-id-type="pmc">2363978</article-id><article-id pub-id-type="pii">6692150</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2150</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oberlin</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deley</surname><given-names>M C Le</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bui</surname><given-names>B N'Guyen</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gentet</surname><given-names>J C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Philip</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Terrier</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Carrie</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mechinaud</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Schmitt</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Babin-Boillettot</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Michon</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib></contrib-group><aff id="aff1"><label>1</label>P&#x000e9;diatrie Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, 94805</aff><aff id="aff2"><label>2</label>D&#x000e9;partement de statistiques Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, 94805</aff><aff id="aff3"><label>3</label>Oncologie, Fondation Bergoni&#x000e9;, 180 Route de Saint Gen&#x000e8;s, Bordeaux Cedex, 33076</aff><aff id="aff4"><label>4</label>Oncologie, Hopital d'Enfants de La Timone, Avenue Jean Moulin, Marseille Cedex, 13385</aff><aff id="aff5"><label>5</label>P&#x000e9;diatrie Centre L&#x000e9;on B&#x000e9;rard, 28 rue Laennec, Lyon Cedex 08, 69008</aff><aff id="aff6"><label>6</label>Anatomie Pathologique Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, 94805</aff><aff id="aff7"><label>7</label>Radioth&#x000e9;rapie, Centre L&#x000e9;on B&#x000e9;rard, 28 rue Laennec, Lyon Cedex 08, 69373</aff><aff id="aff8"><label>8</label>Oncologie P&#x000e9;diatrique CHR, Quai Moncousu, Nantes Cedex, 44035</aff><aff id="aff9"><label>9</label>M&#x000e9;decine Infantile Hopital d'Enfants, Rue du Morvan, Vandoeuvre Cedex, 54511</aff><aff id="aff10"><label>10</label>Onco-H&#x000e9;matologie, Hopital de Hautepierre, Avenue Moli&#x000e8;re, Strasbourg Cedex, 67098</aff><aff id="aff11"><label>11</label>P&#x000e9;diatrie Institut Curie, 26 rue d'Ulm, Paris Cedex 05, 75231, France</aff><pub-date pub-type="ppub"><month>11</month><year>2001</year></pub-date><volume>85</volume><issue>11</issue><fpage>1646</fpage><lpage>1654</lpage><history><date date-type="received"><day>08</day><month>05</month><year>2001</year></date><date date-type="rev-recd"><day>02</day><month>08</month><year>2001</year></date><date date-type="accepted"><day>18</day><month>09</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p><italic>Purpose</italic>: (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to peform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies. <italic>Patients and methods</italic> One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150&#x02008;mg/m<sup>2</sup> &#x000d7; 7 days, followed by Doxorubicin, 35&#x02008;mg/m<sup>2</sup> i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months. <italic>Results</italic> After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66&#x00025; and disease-free survival (DFS) was 58&#x00025;. In patients treated by surgery, only the histological response to CT had an influence on survival: 75&#x00025; DFS for patients with a good histological response (less than 5&#x00025; of cells), 48&#x00025; for intermediate responders and only 20&#x00025; for poor responders (&#x02265; 30&#x00025; of cells), <italic>P</italic> &#x0003c; 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. <italic>Conclusion</italic> Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>Ewing's tumour</kwd><kwd>chemotherapy</kwd><kwd>prognostic factors</kwd></kwd-group></article-meta></front></article>


